AAアミロイドーシス診療ファイル 難治性炎症診療のエッセンス

出版社: 金芳堂
著者:
発行日: 2022-08-08
分野: 臨床医学:内科  >  膠原病/リウマチ
ISBN: 9784765319164
電子書籍版: 2022-08-08 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:約3営業日

5,060 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,060 円(税込)

商品紹介

AASAA(AAアミロイド―シスと血清アミロイドA)研究会メンバーによる集大成
本書のコンセプトは言うまでもなく、多彩な病態を示すAAアミロイドーシスについての対応のノウハウを伝えることにある。「アミロイドーシスを除外する」と言われても、そんな難治性疾患に出会ったことがない臨床医のために、AAアミロイドーシスがどんな経緯を辿るのか、全身満遍なく症例と診断ポイントをまとめた

目次

  • 総論
    01 AAアミロイドーシス診療マニュアル
    A.基礎疾患の疫学
    B.臨床症状
    C.生命予後と死因
    D.診断
    E.治療法の原則
    F.治療法(RAおよびリウマチ性疾患、診断不明例など)
    G.治療法(他の原疾患別)

    02 AAアミロイドーシスの発症病理
    A.アミロイドーシスとは
    B.アミロイドーシス発症病理総論
    C.AA アミロイドーシスとその発症病理
    D.おわりに

    各論
    FILE01 遺伝的素因が強く影響したAAアミロイドーシス合併Caplan症候群の一例
    患者 72歳、男性
    身体所見
    入院時検査結果
    画像所見
    生理学的検査
    その他
    遺伝学的検査
    経過
    考察

    FILE02 AAアミロイドーシスを合併した原発性硬化性胆管炎の一例
    患者 69歳、男性
    入院時検査結果
    画像所見
    遺伝学的検査
    考察

    FILE03 膀胱大量出血を来たした症例
    患者 52歳、女性 47歳、女性 58歳、女性
    考察

    FILE04 AA沈着陽性を長期継続的に認めるRA症例
    患者 72歳、女性
    入院時検査結果
    画像所見
    経過
    考察
    おわりに

    FILE05 血液透析に導入された関節リウマチ合併AAアミロイドーシス症例
    患者 82歳、女性
    身体所見
    入院時検査結果
    経過
    考察

    FILE06 褥瘡や尿路からの感染症によるAAアミロイドーシスの症例
    患者 55歳、女性
    身体所見
    入院時検査結果
    画像所見
    病理検査
    経過
    考察

    FILE07 原発不明癌によるAAアミロイドーシスと蛋白漏出性胃腸症の症例
    患者 66歳、女性
    身体所見
    入院時検査結果
    画像所見
    経過
    考察

    FILE08 全身性エリテマトーデスに関節リウマチを合併したAAアミロイドーシス症例
    患者 66歳、女性
    身体所見
    入院時検査結果
    画像所見
    経過
    考察

    FILE09 AA型アミロイドーシスに伴う微細病変を全消化管に認めた長期罹患の
         クローン病患者の一例
    患者 70歳代、男性
    入院時検査結果
    画像所見
    経過
    考察

    FILE10 トシリズマブが奏効した若年性特発性関節炎に続発したAAアミロイドーシス患者
         ―長期経過も含めて―
    患者 25歳、女性
    身体所見
    入院時検査結果
    画像所見
    経過
    考察

    FILE11 強皮症を合併したAAアミロイドーシス症例
    患者 67歳、女性
    身体所見
    入院時検査結果
    画像所見
    生検所見
    経過
    考察

    FILE12 ネフローゼ症候群を発症した特発性多中心性Castleman病の一例
    患者 49歳、女性
    身体所見
    入院時検査結果
    画像所見
    経過
    考察

    FILE13 消化管アミロイドーシスを合併しトシリズマブの投与で症状の改善を認めた
         べーチェット病の一例
    患者 44歳、女性
    入院時検査所見
    画像所見、内視鏡所見
    遺伝学的検査
    経過
    考察

    FILE14 AAアミロイドーシスを合併したPlasma cell dyscrasiaの一例
    患者 59歳、男性
    入院時検査結果
    画像所見
    骨髄穿刺
    考察

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.9 掲載の参考文献
1) Gertz MA, et al. Secondary systemic amyloidosis : response and survival in 64 patients. Medicine (Baltimore). 1991 ; 70 : 246-256.
2) 豊島元. 剖検輯報からみた慢性関節リウマチの死因-とくにアミロイドーシスとの関連から-. リウマチ 1993 ; 33 : 209-214.
3) 北浜真理子, 他. AAアミロイドーシス臨床像の年代別変化. リウマチ学会 2007プログラム・抄録集. 2007 ; p.282.
4) Okuda Y, et al. First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Intern Med. 2018 ; 57 : 3351-3355.
5) Lane T, et al. Changing epidemiology of AA amyloidosis : clinical observations over 25 years at a single national referral centre. Amyloid. 2017 ; 24 : 162-166.
6) Okuda Y, et al. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis. 1997 ; 56 : 535-541.
7) Looi LM. Histomorphological variations in systemic AA amyloidosis : clue of AA protein polymorphism. Histopathology. 1989 ; 14 : 111-120.
8) Uda H, A, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006 ; 33 : 1482-1487.
9) Verine J, et al. Clinical and histological characteristics of renal AA amyloidosis : a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol. 2007 ; 38 : 1798-1809.
10) Ueno T, et al. Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant. 2012 ; 27 : 633-639.
11) Tiitinen S, et al. Amyloidosis-incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol. 1993 ; 22 : 158-161.
12) Tanaka F, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003 ; 21 : 343-346.
13) 奥田恭章. リウマチ医が知るべき関節リウマチの臓器合併症-その診断・治療・予防 二次性アミロイドーシス (反応性AAアミロイドーシス). リウマチ科 2011 ; 46151 : 501-509.
14) Kuroda T, et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2006 ; 25 : 498-505.
15) Kofman T, et al. Renal transplantation in patients with AA amyloidosis nephropathy : results from a French multicenter study. Am J Transplant. 2011 ; 11 : 2423-2431.
16) 奥田恭章. 慢性関節リウマチに合併した2次性アミロイドーシス124例の臨床的検討-胃十二指腸生検による診断と予後を中心として-. リウマチ 1994 ; 34 : 939-946.
17) Kuroda T, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol. 2002 ; 21 : 123-128.
18) Gillmore JD, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 ; 358 : 24-29.
19) Gottenberg JE, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides : a followup report of tolerability and efficacy. Arthritis Rheum. 2003 ; 48 : 2019-2024.
20) Fernandez-Nebro A, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010 ; 123 : 454-461.
21) Okuda Y, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 ; 24 : 137-143.
22) Okuda Y, et al. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 ; 54 : 2997-3000.
23) Nishida S, et al. Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009 ; 68 : 1235-1236.
24) 奥田恭章. AAアミロイドーシス合併関節リウマチ症例におけるアミロイド蛋白のターンオーバーと除去. 別冊・医学のあゆみ アミロイドーシス UPDATE 2010. pp35-38.
25) Kuroda T, et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int. 2006 ; 26 : 1147-1153.
26) 奥田恭章. 関節リウマチに伴うAAアミロイドーシス. 胃と腸 2014 ; 49 : 335-343.
P.23 掲載の参考文献
1) 荒木淑郎. アミロイドーシス : 研究の歴史的展望. 石原得博 (監). アミロイドーシスの基礎と臨床. 金原出版, 2005, pp.2-7.
2) 大橋健一. アミロイドーシスの病理紹介, 病型分類. 病理と臨床 2016 ; 34 : 472-480.
3) Benson MD. Amyloidosis. In : The Metabolic Basis of Inherited Disease 7th ed. McGraw-Hill, Inc. 1995. pp. 4159-4191.
4) Westermark GT, et al. AA amyloidosis : pathogenesis and targeted therapy. Annu Rev Pathol. 2015 ; 10 : 321-344.
5) 安東由喜雄. アミロイドーシスの分類. 最新 アミロイドーシスのすべて. 医歯薬出版, 2017, pp2-8.
6) 安東由喜雄, 他. アミロイドーシスにおける早期診断システムと診療支援の重要性. http://amyloidosis-research-committee.jp/wp-content/uploads/2018/02/2013_H25_24_misumi.pdf (2022年3月14日閲覧)
7) 関島良樹. 不治の病から治療可能な疾患に-アミロイドーシスをめぐる病態と診療の最前線-. 自律神経 2020 ; 57 : 114-118.
8) Okuda Y, et al. Ageing : a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011 ; 18 : 108-111.
9) Oza VB, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem. 2002 ; 45 : 321-332.
10) Gillmore JD, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 ; 358 : 24-29.
11) Kisilevsky R, et al. Acute-phase amyloid A : perspectives on its physiological and pathological roles. Amyloid. 2012 ; 19 : 5-14.
12) Yoshizaki K. Pathogenic role of IL-6 combined with TNF-α or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv Exp Med Biol. 2011 ; 691 : 141-159.
13) Okuda Y, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 ; 24 : 137-143.
14) Kisilevsky R, et al. Serum amyloid A changes high density lipoprotein's cellular affinity. Lab Invest. 1992 ; 66 : 778-785.
15) Jayaraman S, et al. Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA. J Lipid Res. 2016 ; 57 : 2138-2149.
16) Snow AD, et al. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem. 1991 ; 39 : 1321-1330.
17) Noborn F, et al. Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. J Biol Chem. 2012 ; 287 : 25669-25677.
18) Yamada T, et al. In vitro degradation of serum a myloid A by cathepsin D and other acid proteases : possible protection against amyloid fibril formation. Scand J Immunol. 1995 ; 41 : 570-574.
19) Yamada T, et al. Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol. 1996 ; 157 : 901-907.
20) Okuda Y, et al. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 ; 54 : 2997-3000.
21) Sato J, et al. Accumulation and absorption of serum amyloid A and apolipoprotein E fragments in the course of AA amyloidosis : a study in a mouse model. Ann Clin Lab Sci. 2014 ; 44 : 249-253.
22) Nystrom SN, et al. AA-amyloid is cleared by endogenous immunological mechanisms. Amyloid. 2012 ; 19 : 138-145.
23) 山田俊幸. 血清アミロイドAの多型. 臨床検査 2002 ; 46 : 1021-1024.
24) Liepnieks JJ, et al. Characterization of amyloid A protein in human secondary amyloidosis : the predominant deposition of serum amyloid A1. Biochim. Biophys. Acta. 1995 ; 1270 : 81-86.
25) Xu Y, et al. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA. Clin Chem Lab Med. 2006 ; 44 : 59-63.
26) Lu J, et al. Structural mechanism of serum amyloid A- mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A. 2014 ; 111 : 5189-5194.
27) Westermark GT, et al. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun. 1992 ; 182 : 27-33.
28) Baba S, et al. A novel allelic variant of serum amyloid A, SAA1 gamma : genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995 ; 4 : 1083-1087.
29) 奥田恭章, 他. 慢性関節リウマチに合併した二次性アミロイドーシスにおけるSAA1, SAA2, アポリポ蛋白Eの遺伝多型と疾患感受性の検討. リウマチ 1999 ; 39 : 3-10.
30) Moriguchi M, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position -13 (T/C) : potential association between increased transcription and amyloidosis. Amyloid. 2005 ; 12 : 26-32.
31) Ishii W, et al. Human SAA1-derived amyloid deposition in cell culture : a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium. Amyloid. 2013 ; 20 : 61-71.
32) Takase H, et al. Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties. Biochem Biophys Res Commun. 2014 ; 444 : 92-97.
33) Yamada T, et al. Relative serum amyloid A (SAA) values : the influence of SAA1 genotypes a nd c orticosteroid t reatment i n J apanese p atients w ith r heumatoid arthritis, Ann Rheum Dis. 2001 ; 60 : 124-127.
34) Kluve-Beckerman B, et al. Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2. Biochem J. 1997 ; 322 : 663-669.
35) Yamada T, et al. Slower clearance of human SAA1.5 in mice : Implication for allele specific variation of SAA concentration in human. Amyloid. 2003 ; 10 : 147-150.
36) Yamada T, et al. Differential affinity of serum amyloid A1 isotypes for high-density lipoprotein. Amyloid. 2009 ; 16 : 196-200.
37) van der Hilst JC, et al. Increased susceptibility of serum amyloid 1.1 to degradation by MMP-1 : potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford). 2008 ; 47 : 1651-1654.
38) Booth DR, et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998 ; 5 : 262-265.
39) Sato J, et al. Detection of AA76, a common form of amyloid A protein, as a way of diagnosing AA amyloidosis. Ann Clin Lab Sci. 2016 ; 46 : 147-153.
40) Yamada T, et al. Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol. 1995 ; 41 : 94-97.
41) Tanaka M, et al. Acceleration of amyloid fibril formation by carboxyl-terminal truncation of human serum amyloid A. Arch Biochem Biophys. 2018 ; 639 : 9-15.
42) Westermark GT, et al. Massive vascular AA-amyloidosis : a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol. 1989 ; 30 : 605-613.
43) Zhang B, et al. Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. Proc Natl Acad Sci U S A. 2008 ; 105 : 7263-7268.

各論

P.34 掲載の参考文献
1) Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax. 1953 ; 8 : 29-37.
2) Nakamura T, et al. Amyloid A amyloidosis in a patient with Caplan's syndrome, with special reference to genetic predisposition. Mod Rheumatol Case Rep. 2020 ; 4 : 212-217.
3) Nakamura T, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006 ; 45 : 43-49.
4) Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis : pathophysiology and treatments. Clin Exp Rheumatol. 2011 ; 29 : 850-857.
5) Nakamura T, et al. Systemic AA amyloidosis secondary to rheumatoid arthritis may be treatable but is still difficult to manage in daily clinical practice. Amyloid. 2019 ; 26 (Suppl 1) : S123-S124.
6) Ondrasik M. Caplan's syndrome. Bailliere's Clin Rheumatol. 1989 ; 3 : 205-210.
7) Schreiber J, et al. Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med. 2010 ; 21 : 168-172.
8) Migita K, et al. Familial Mediterranean fever. genotype-phenotype correlations in Japanese patients. Medicine (Baltimore). 2014 ; 93 : 158-164.
9) Okuda Y. AA amyloidosis-benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019 ; 29 : 268-274.
P.40 掲載の参考文献
1) Kato T, et al. Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis. World J Gastroenterol. 2012 ; 18 : 192-196.
2) Wallace ZS, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020 ; 79 : 77-87.
3) Zen Y, et al. Immunoglobulin G4-positive plasma cell infiltration in explanted livers for primary sclerosing cholangitis. Histopathology. 2011 ; 58 : 414-422.
4) Van Steenbergen W, et al. Primary sclerosing cholangitis complicated by amyloid A amyloidosis : complete regression of the nephrotic syndrome by liver transplantation. Eur J Gastroenterol Hepatol. 2010 ; 22 : 1265-1270.
5) Fousekis FS, et al. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease : A Review. Gastroenterology Res. 2018 ; 11 : 83-94.
6) Ghazale A, et al. Immunoglobulin G4-associated cholangitis : clinical profile and response to therapy. Gastroenterology. 2008 ; 134 : 706-715.
7) Okuda Y, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 ; 24 : 137-143.
P.44 掲載の参考文献
1) Nurmi MJ, et al. Secondary amyloidosis of the bladder : a cause of massive hematuria. J Urol. 1987 ; 138 : 44-45.
2) 中山田真吾, 他. 関節リウマチに併発した二次性膀胱アミロイド症の一症例. リウマチ 2002 ; 42 : 618-623.
3) Nakamura T, et al. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis : three case reports. Clin Exp Rheumatol. 2003 ; 21 : 673-674.
4) Nakamura T, et al. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2004 ; 14 : 498-501.
5) Nakamura T, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006 ; 45 : 43-49.
6) Nagy G, et al. EULAR definition of difficult-to treat rheumatoid arthritis. Ann Rheum Dis. 2021 ; 80 : 31-35.
7) Steinbrocker O, et al. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949 ; 140 : 659-662.
P.52 掲載の参考文献
1) Nakamura T, et al. Alpha 1-acid glycoprotein expression in human leukocytes : possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis. Inflammation. 1993 ; 17 : 33-45.
2) Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis : an uncommon yet important complication. Curr Rheumatol Rev. 2007 ; 3 : 231-241.
3) Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis : pathophysiology and treatment. Clin Exp Rheumatol. 2011 ; 29 : 850-857.
4) Nakamura T, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006 ; 45 : 43-49.
5) Nakamura T, et al. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010 ; 29 : 1395-1401.
6) Yamada T, et al. Relative serum amyloid A (SAA) values : the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2001 ; 60 : 124-127.
7) Amin HZ, et al. Diagnostic approach to cardiac amyloidosis. Kobe J Med Sci. 2014 ; 60 : E5-E11.
P.58 掲載の参考文献
1) Kuroda T, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. Amyloid. 2017 ; 24 : 123-130.
2) Kuroda T, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol. 2002 ; 21 : 123-128.
3) Kuroda T, et al. Effective anti-TNF- alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol. 2009 ; 36 : 2409-2915.
4) Kuroda T, et al. Programmed initiation of hemodialysis for systemic amyloidosis patients associated with rheumatoid arthritis. Rheumatol Int. 2011 ; 31 : 1177-1182.
5) Kuroda T, et al. Effects of biologic agents in patients with rheumatoid arthritis and amyloidosis treated with hemodialysis. Internal Med. 2016 ; 55 : 2777-2783.
P.67 掲載の参考文献
1) Okuda Y, et al. First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Intern Med. 2018 ; 57 : 3351-3355.
2) Lachmann HJ, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 ; 356 : 2361-2371.
3) 斉藤那由多, 他. 慢性進行性肺アスペルギルス症に合併した続発性アミロイドーシスの1例. 日呼吸会誌 2016 ; 5 : 336-340.
4) Tuchiya Y, et al. AA-amyloidosis in autosomal dominant polycystic kidney disease caused by chronic cyst infections lasting for 30 years. Intern Med. 2013 ; 52 : 791-794.
5) Nishimura S, et al. Chronic renal failure due to amyloid nephropathy caused by chronic infection after total hip replacement. CEN Case Rep. 2014 ; 3 : 217-222.
6) 上山貴嗣, 他. シスチン尿症を基礎に複雑性尿路感染症からAAアミロイドーシスを合併した一例. 日病総合診療医会誌 2016 ; 10 : 46-49.
7) 厚生労働科学研究費補助金 難治性疾患克服研究事業 アミロイドーシスに関する調査研究班編. アミロイドーシス診療ガイドライン 2010 ; pp.14-19.
8) 飯田三男. アミロイドーシスの消化管病変. 千葉勉, 他編. 消化器疾患診療実践ガイド. 2005, 文光堂, pp.811-812.
9) Imai H, et al. Nephrotic syndrome : Renal amyloidosis and monoclonal immunoglobulin deposition disease. 日腎会誌 2014 ; 56 : 493-499.
10) Kendi Celebi Z, et al. Kidney biopsy in AA amyloidosis : impact of histopathology on prognosis. Amyloid. 2017 ; 24 : 176-182.
大越貴絵, 他. 尿路感染と褥瘡の治療により蛋白尿が消失したAAアミロイドーシスの1例. 日内会誌 2019 ; 108 : 1442-1447.
P.75 掲載の参考文献
1) Pinney JH, et al. Systemic AA amyloidosis. Subcell Biochem. 2012 ; 65 : 541-564.
2) Shiroshita A, et al. A case of protein-losing gastroenteropathy caused by systemic AA amyloidosis secondary to undifferentiated carcinoma of unknown primary origin. Oxf Med Case Reports. 2019 ; 2019 : omz074.
3) Braamskamp MJ, et al. Clinical practice. Protein-losing enteropathy in children. Eur J Pediatr. 2010 ; 169 : 1179-1185.
4) Umar SB, et al. Protein-losing enteropathy : case illustrations and clinical review. Am J Gastroenterol. 2010 ; 105 : 43-49 ; quiz 50.
5) Wechalekar AD, et al. Systemic amyloidosis. Lancet. 2016 ; 387 : 2641-2654.
6) Gillmore JD, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 ; 358 : 24-29.
P.81 掲載の参考文献
1) Kuroda T, et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis.Clin Rheumatol. 2002 ; 21 : 123-128.
2) Huston DP, et al. Amyloidosis in systemic lupus erythematosus. Am J Med. 1981 ; 70 : 320-323.
3) Aktas Yilmaz B, et al. AA amyloidosis associated with systemic lupus erythematosus : impact on clinical course and outcome. Rheumatol Int. 2008 ; 28 : 367-370.
P.86 掲載の参考文献
1) Greenstein AJ, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992 ; 71 : 261-270.
2) Miyaoka M, et al. Clinical and endoscopic features of amyloidosis secondary to Crohn's disease : diagnostic value of duodenal observation and biopsy. Dig Endosc. 2011 ; 23 : 157-165.
3) 平井郁仁, 他. 炎症性腸疾患に伴う二次性アミロイドーシスの臨床的検討-Crohn病症例の合併率, 形態診断, 長期経過を中心に. 胃と腸 2014 ; 49 : 345-357.
4) 山本淳也, 他. Crohn病に合併した続発性アミロイドーシス11例の臨床的検討. 胃と腸 1999 ; 34 : 1255-1266.
5) Tosca Cuquerella J, et al. Amyloidosis in Inflammatory Bowel Disease : A Systematic Review of Epidemiology, Clinical Features, and Treatment. J Crohns Colitis. 2016 ; 10 : 1245-1253.
P.93 掲載の参考文献
1) 小中八郎, 他. トシリズマブにより肉眼的血尿が改善したAAアミロイドーシス膀胱病変を伴う成人期若年性特発性関節炎の一例. 臨床リウマチ 2017 ; 29 : 45-51.
2) Okuda Y, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 ; 24 : 137-143.
3) 中山田真吾, 他. 関節リウマチに併発した二次性膀胱アミロイド症の一症例. リウマチ 2002 ; 42 : 618-623.
4) Okuda Y, et al. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 ; 54 : 2997-3000.
P.99 掲載の参考文献
Wada Y, et al. Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis : the therapeutic potential of biological reagents. Scand J Rheumatol. 2011 ; 40 : 402-404.
P.107 掲載の参考文献
1) Furutera N, et al. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. CEN Case Rep. 2021 ; 10 : 35-41.
2) Fajgenbaum DC, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 ; 129 : 1646-1657.
3) Xu D, et al. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant. 2012 ; 27 (Suppl 3) : iii119-125.
4) Nishimoto N, et al. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008 ; (181) : 151-160.
5) Nishimoto N, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005 ; 106 : 2627-2632.
6) Yamada Y, et al. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease : A case report. Clin Nephrol. 2018 ; 90 : 232-236.
7) van Rhee F, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 ; 132 : 2115-2124.
Furutera N, et al. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab. CEN Case Rep. 2021 ; 10 : 35-41.
P.113 掲載の参考文献
1) Suzuki E, et al. Effectiveness of tocilizumab for Behcet disease complicated by amyloidosis in the intestinal tract : A case report. Medicine Case Reports and Study Protocols. 2020 ; 1 : e0022.
2) Satoskar AA, et al. Typing of amyloidosis in renal biopsies : diagnostic pitfalls. Arch Pathol Lab Med. 2007 ; 131 : 917-922.
3) Akpolat T, et al. Behcet's disease and AA-type amyloidosis. Am J Nephrol. 2000 ; 20 : 68-70.
4) Nakamura T, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006 ; 45 : 43-49.
5) Kosemehmetoglu K, et al. Renal amyloidosis in Behcet's disease : clinicopathologic features of 8 cases. Int Urol Nephrol. 2013 ; 45 : 785-794.
6) Vallet H, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease : Multicenter study of 124 patients. J Autoimmun. 2015 ; 62 : 67-74.
7) Okuda Y, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 ; 24 : 137-143.
8) Redondo-Pachon MD, et al. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease. Ren Fail. 2013 ; 35 : 547-550.
P.118 掲載の参考文献
1) Ishikawa H, et al. Amyloid a protein amyloidosis in a patient with plasma cell dyscrasia. Intern Med. 2002 ; 41 : 386-391.
2) 鈴木憲史. 多発性骨髄腫の関連疾患. 日内会誌 2016 ; 105 : 1231-1237.
3) Dispenzieri A, et al. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012 ; 26 : 137-154.
4) Gertz, MA. Immunoglobulin light chain amyloidosis : 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013 ; 88 : 416-425.
5) Riveiro-Barciela M, et al. Nephrotic syndrome and lambda light-chain monoclonal gammopathy suggestive of primary amyloidosis with positive staining for AA amyloid. J Am Geriatr Soc. 2012 ; 60 : 1974-1975.
6) Bernabei L, et al. AA amyloidosis associated with Castleman disease : A case report and review of the literature. Medicine (Baltimore). 2020 ; 99 : e18978.

サイドノート AAアミロイドーシスの原因

P.120 掲載の参考文献
Brunger AF, et al. Causes of AA amyloidosis : a systematic review. Amyloid. 2020 ; 27 : 1-12.

最近チェックした商品履歴

Loading...